AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis

뉴스 본문을 불러오고 있어요.

AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis | 웨이프 WAPE

AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis

기사 요약

관련 종목

댓글 —